[go: up one dir, main page]

EP0998457A1 - Formes cristallines d'intermediaires a chaine laterale antibiotiques - Google Patents

Formes cristallines d'intermediaires a chaine laterale antibiotiques

Info

Publication number
EP0998457A1
EP0998457A1 EP98933212A EP98933212A EP0998457A1 EP 0998457 A1 EP0998457 A1 EP 0998457A1 EP 98933212 A EP98933212 A EP 98933212A EP 98933212 A EP98933212 A EP 98933212A EP 0998457 A1 EP0998457 A1 EP 0998457A1
Authority
EP
European Patent Office
Prior art keywords
crystalline
pyrrolidinyl
mercapto
cis
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98933212A
Other languages
German (de)
English (en)
Other versions
EP0998457A4 (fr
Inventor
Karel M. J. Brands
Ronald B. Jobson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9800463.3A external-priority patent/GB9800463D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0998457A1 publication Critical patent/EP0998457A1/fr
Publication of EP0998457A4 publication Critical patent/EP0998457A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Definitions

  • Crystalline forms of intermediates for carbapenem antibiotics are desirable from a stability and purity standpoint. These compounds facilitate the synthesis of carbapenem antibiotics on a commercial scale.
  • crystalline forms of the compound 2S-cis-3-[[(4-mercapto-2-pyrrolidinyl)carbonyl]-amino] benzoic acid have been discovered and characterized.
  • Crystalline 2S-cis-3-[[(4-mercapto-2-pyrrolidinyl)carbonyl]-amino]benzoic acid and pharmaceutically acceptable salts and solvates thereof are disclosed.
  • the compounds can generally be synthesized taking into account the disclosure of U. S. Patent No. 5,478,820 granted on December 26, 1995. This patent does not disclose the side chain in crystalline form.
  • Figure 1 is an X-Ray Powder Diffraction pattern of Compound I, in unsolvated form
  • Figure 2 is an X-Ray Powder Diffraction pattern of Compound I as the 1-butanol solvate
  • Figure 3 is an X-Ray Powder Diffraction pattern of Compound I, as the acetic acid solvate.
  • the compound has the following structural formula:
  • the salt form of the compound can be protonated as shown in the following:
  • X represents a negatively charged counterion.
  • the salt forms can also be present in the form of a solvate.
  • the crystalline forms of the compound are characterized below by virtue of their X-Ray Powder Diffraction (XRPD) patterns.
  • the XRPD patterns were collected on a Philips APD 3720 automated powder diffractometer.
  • the x-ray generator employed a copper target, an accelerating potential of 45 kV and a filament emission of 40 mA. Diffraction patterns were collected from 2°C to 40°C.
  • the hydrochloride salt of the compound (unsolvated material) was characterized as having an XRPD pattern at 5.5, 5.3, 4.9, 4.3, 4.1, 3.9, 3.8, 3.7, 3.6, 3.3, 3.2, 2.9, 2.6 and 2.3 angstroms. More complete XRPD data pertaining to the compound is shown below in Table 1.
  • Step size sample time 0.015 deg, 0.20 s, 0.075 deg/s
  • the hydrochloride salt 1-butanol solvate was shown to exhibit patterns such as the ERPD pattern shown as Figure 2. Characteristic D-spacings are 14.6, 7.3, 5.6, 4.9, 4.2, 4.0, 3.9, 3.8, 3.7, 3.6, 3.5, 3.3, 3.0 and 2.9 Ang. More complete XRPD data pertaining to the solvate is shown below in Table 2.
  • Step size sample time 0.015 deg, 0.20 s, 0.075 deg/s
  • Solid material which was exposed to acetic acid was characterized as having an XRPD pattern at 5.4, 5.3, 5.1, 4.2, 3.8, 3.6, 3.4, 3.1, 2.7 and 2.6 angstroms. More complete XRPD data pertaining to the solvate is shown below in Table 3.
  • Peak position criterion Top of smoothed data Cryst peak width range 0.00-2.00 deg
  • the crystalline compound of the present invention is useful in various pharmaceutically acceptable salt forms, for the synthesis of carbapenem compounds that are in turn useful for the treatment of bacterial infections in animal and human subjects.
  • pharmaceutically acceptable salt refers to those salt forms which would be apparent to the pharmaceutical chemist, i.e., those which are substantially non-toxic and which provide the desired pharmacokinetic properties, palatability, absorption, distribution, metabolism or excretion.
  • Other factors, more practical in nature, which are also important in the selection, are cost of the raw materials, ease of crystallization, yield, stability, hygroscopicity and flowability of the resulting bulk drug.
  • the intermediate compound is protonated, and is found in association with a negatively charged counterion, represented by the generic X".
  • a negatively charged counterion represented by the generic X.
  • charge balancing counterion X Representative examples of such counterions are the following: acetate, adipate, aminosalicylate, anhydromethylenecitrate, ascorbate, aspartate, benzoate, benzenesulfonate, bicarbonate, bisulfate, bromide, citrate, camphorate, camphorsulfonate, carbonate, chloride, digluconate, edetate, edisylate, estolate, ethanesulfonate, fumarate, glucoheptanoate, gluconate, glutamate, glycerophosphate, glycolate, hydroxynaphthoate, 2-hydroxyethanesulfonate, iodide, lactate, lactobionate, malate, maleate, man
  • the preferred form of the crystalline compound is the hydrochloride salt form.
  • the compound can be produced in accordance with the following non-limiting examples.
  • the BOC protected sidechain 1 (prepared according to the teachings of PCT WO97/06154 published on February 20, 1997) was dissolved in 1.5 L of a 1 N solution of dry hydrogen chloride in acetic acid (30 min). Gas evolution was observed and the reaction product slowly crystallized. After filtering, washing (with acetic acid and hexane) and drying 137 g of product was obtained. The crystals contain acetic acid but are not a solvate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

L'invention concerne un acide 2S-cis-3[[(4-mercapto-2-pyrrolidinyl) carbonyl]-amino]benzoïque cristallin, ainsi que ses sels et ses solvates. L'invention concerne également trois types cristallins différents.
EP98933212A 1997-07-10 1998-07-07 Formes cristallines d'intermediaires a chaine laterale antibiotiques Withdrawn EP0998457A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5219797P 1997-07-10 1997-07-10
US52197P 1997-07-10
GBGB9800463.3A GB9800463D0 (en) 1998-01-09 1998-01-09 Crystalline forms of antibiotic side chain intermediates
GB9800463 1998-01-09
PCT/US1998/014036 WO1999002492A1 (fr) 1997-07-10 1998-07-07 Formes cristallines d'intermediaires a chaine laterale antibiotiques

Publications (2)

Publication Number Publication Date
EP0998457A1 true EP0998457A1 (fr) 2000-05-10
EP0998457A4 EP0998457A4 (fr) 2010-03-10

Family

ID=26312922

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98933212A Withdrawn EP0998457A4 (fr) 1997-07-10 1998-07-07 Formes cristallines d'intermediaires a chaine laterale antibiotiques

Country Status (5)

Country Link
EP (1) EP0998457A4 (fr)
JP (1) JP3378021B2 (fr)
AU (1) AU736136B2 (fr)
CA (1) CA2294341C (fr)
WO (1) WO1999002492A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0112580A (pt) 2000-07-19 2003-06-17 Hoffmann La Roche Compostos, composições farmacêuticas que contêm os mesmos, utilização desses compostos, processo para tratamento terapêutico e/ou profilático e processo para a preparação desses compostos
WO2010073706A1 (fr) * 2008-12-25 2010-07-01 株式会社カネカ Procédé de production amélioré d'un intermédiaire pour chaîne latérale de carbapénème

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9202298D0 (en) * 1992-02-04 1992-03-18 Ici Plc Antibiotic compounds
CA2294342C (fr) * 1997-07-09 2006-03-14 Merck & Co., Inc. Procede de synthetisation d'intermediaires de carbapenem a chaine laterale

Also Published As

Publication number Publication date
AU8292098A (en) 1999-02-08
CA2294341C (fr) 2007-09-25
JP2002504157A (ja) 2002-02-05
EP0998457A4 (fr) 2010-03-10
JP3378021B2 (ja) 2003-02-17
CA2294341A1 (fr) 1999-01-21
AU736136B2 (en) 2001-07-26
WO1999002492A1 (fr) 1999-01-21

Similar Documents

Publication Publication Date Title
US4721723A (en) Anti-depressant crystalline paroxetine hydrochloride hemihydrate
DE69924751T2 (de) Cephemverbindungen mit einem imidazo[4,5-b]pyridiniummethyl-rest, die ein breites antibakterielles wirkungsspektrum haben
RS56803B1 (sr) Postupak za proizvodnju 2-[4-(3-ili2-fluorobenziloksi)benzilamino] propanamida sa visokim stepenom čistoće
EP2240431B1 (fr) Modifications cristallines de (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phénol
HRP20030575A2 (en) Preparation of non-crystalline atorvastatin calcium
AU2002219455A1 (en) Preparation of non-crystalline atorvastatin calcium
JP6985179B2 (ja) プロリンアミド化合物の製造方法
US5965747A (en) Crystalline forms of antibiotic side chain intermediates
CA2294341C (fr) Formes cristallines d'intermediaires a chaine laterale antibiotiques
CA1329617C (fr) Agents neuroprotecteurs a base d'aminopyrrolidine pure
US6479667B2 (en) Crystalline forms of antibiotic side chain intermediates
Favero et al. Stereoselective synthesis of dipeptides—I
EA021810B1 (ru) Комплексы вилдаглиптина с неорганической солью
WO2020065667A1 (fr) Nouveaux polymorphes d'acalabrutinib, un inhibiteur de la tyrosine kinase de bruton
KR20190064589A (ko) 4-(2-((1r,2r)-2-히드록시시클로헥실아미노)벤조티아졸-6-일옥시)-n-메틸피콜린아미드의 결정질 형태
EP3168210A1 (fr) Formes crystallines de l'entinostat
AU2023352643A1 (en) Novel co-crystal of enavogliflozin
DD260066A5 (de) Verfahren zur herstellung substituierter pyrrolidinone
WO2007005863A1 (fr) Formes cristallines de monohydrochlorure de (2r-trans)-6-chloro-5[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n, 1-trimethyl-alpha-oxo-1h-indole-3-acetamide
WO2002020476A2 (fr) Formes cristallines d'intermediaires de carbapenem
WO2013095307A1 (fr) Nouveaux sels cristallins de zofénopril, procédé pour les obtenir et leur utilisation à des fins de thérapie
WO2001064684A1 (fr) Formes cristallines d'intermediaires a chaines laterales pour des antibiotiques
WO2004089933A1 (fr) Nouveau cristal de derive de fluorobenzamide
HK1235765B (en) Medicaments containing crystalline modifications of (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000210

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20100210

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MERCK SHARP & DOHME CORP.

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 207/16 20060101AFI20100204BHEP

17Q First examination report despatched

Effective date: 20100416

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101027